Assessing the efficacy of spironolactone on adult acne in subjects with polycystic ovary syndrome
Keywords:
Adult acne, Efficacy, polycystic ovary syndrome, spironolactone, overweight femalesAbstract
Aim: The present prospective clinical study was conducted to assess the long‑term spironolactone therapy and its effect with and without dietary‑induced weight‑loss, on insulin levels, lipid profile, and clinical features in females with PCOS (polycystic ovary syndrome). Methods: The present study included 22 females 12 normal weight and 10 obese within the age of 17-32 years having symptoms of PCOS including hyperandrogenism with clinical or biochemical evidence with amenorrhea and/or oligomenorrhea. These subjects were assessed before spironolactone therapy and after 100mg/day spironolactone orally for 12 months. Lifestyle modification was advised for obese females. Before starting and following antiandrogen therapy, metabolic, endocrine, and clinical parameters were assessed. Results: Spironolactone orally resulted in a significant reduction of triglycerides in overweight females and an increase in HDL (high-density lipoproteins) in subjects who were lean and have normal weight. After 12 months of oral spironolactone therapy, the area under the curve of insulin, insulin resistance with hemostasis model, and levels of insulin during OGTT at 60 minutes were significantly reduced in obese females. In females with PCOS following therapy, no negative change in insulin sensitivity and secretion and weight loss was seen after pharmacologic treatment.
Downloads
References
Azziz R, Saenger P. The second international symposium on the developmental aspects of androgen excess, Toronto, Canada, 20 June 2000. Trends Endocrinol Metab 2000;11:338‑40.
Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35: 100937.
Packard CJ, et al. Causes and consequences of hypertriglyceridemia. Front Endocrinol (Lausanne) 2020;11:252
Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids. 2015;2015:971453.
S.S. Lim, M.J. Davies, R.J. Norman, L.J. Moran. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis Human Reproduction Update. 2012;18:618-37.
Legro RS. Polycystic ovary syndrome: The new millennium. Mol Cell Endocrinol 2001;184:87‑93.
Vrbíková J, Cibula D, Dvoráková K, Stanická S, Sindelka G, Hill M, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:2942‑5.
Haas DA, Carr BR, Attia GR. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2003;79:469–81.
Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587–94
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Ganie MA, Khurana ML, Eunice M, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. 2004;89:2756–62.
Ganie MA, Khurana ML, Nisar S, Ahmed Shah P, Amin Shah Z, Kulshrestha B, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013;98:3599–607.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
